Literature DB >> 23500390

The late Na current as a therapeutic target: where are we?

Lars S Maier1, Samuel Sossalla.   

Abstract

In this article we review the late Na current which functionally can be measured using patch-clamp electrophysiology (INa,late). This current is largely enhanced under pathological myocardial conditions such as ischemia and heart failure. In addition, INa,late can cause systolic and diastolic contractile dysfunction via a Na-dependent Ca-overload of the myocyte. Moreover, INa,late plays a crucial role as ventricular and atrial proarrhythmic substrate in myocardial pathology by changing cellular electrophysiology. We summarize recent experimental and clinical studies that investigate therapeutic inhibition of this current and discuss the significance of the available data and try to answer not only the question, where we currently are but also where we may go in the near future. This article is part of a Special Issue entitled "Na(+) Regulation in Cardiac Myocytes".
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angina; Arrhythmias; Heart failure; I(Na,late); Ischemia; Ranolazine

Mesh:

Substances:

Year:  2013        PMID: 23500390     DOI: 10.1016/j.yjmcc.2013.03.001

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  15 in total

1.  Ca2+/calmodulin-dependent kinase II-dependent regulation of atrial myocyte late Na+ current, Ca2+ cycling, and excitability: a mathematical modeling study.

Authors:  Birce Onal; Daniel Gratz; Thomas J Hund
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-08-25       Impact factor: 4.733

Review 2.  Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure.

Authors:  Alexander Dietl; Christoph Maack
Journal:  Curr Heart Fail Rep       Date:  2017-08

3.  Inhibition of late sodium current via PI3K/Akt signaling prevents cellular remodeling in tachypacing-induced HL-1 atrial myocytes.

Authors:  Tae Hee Ko; Daun Jeong; Byeongil Yu; Ji Eun Song; Qui Anh Le; Sun-Hee Woo; Jong-Il Choi
Journal:  Pflugers Arch       Date:  2022-10-24       Impact factor: 4.458

Review 4.  Cardiomyocyte Ca2+ homeostasis as a therapeutic target in heart failure with reduced and preserved ejection fraction.

Authors:  Deborah Peana; Timothy L Domeier
Journal:  Curr Opin Pharmacol       Date:  2017-04-22       Impact factor: 5.547

5.  Nav channel complex heterogeneity: new targets for the treatment of arrhythmia?

Authors:  Thomas J Hund; Peter J Mohler
Journal:  Circulation       Date:  2014-06-03       Impact factor: 29.690

6.  Scn1b expression in the adult mouse heart modulates Na+ influx in myocytes and reveals a mechanistic link between Na+ entry and diastolic function.

Authors:  Daniel O Cervantes; Emanuele Pizzo; Harshada Ketkar; Sreema P Parambath; Samantha Tang; Eleonora Cianflone; Antonio Cannata; Govindaiah Vinukonda; Sudhir Jain; Jason T Jacobson; Marcello Rota
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-04-08       Impact factor: 4.733

7.  Switching from nitrate therapy to ranolazine in patients with coronary artery disease receiving phosphodiesterase type-5 inhibitors for erectile dysfunction.

Authors:  Dioma U Udeoji; Ernst R Schwarz
Journal:  Clin Med Insights Case Rep       Date:  2014-11-19

8.  Antagonism of Nav channels and α1-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine.

Authors:  Anne Virsolvy; Charlotte Farah; Nolwenn Pertuit; Lingyan Kong; Alain Lacampagne; Cyril Reboul; Franck Aimond; Sylvain Richard
Journal:  Sci Rep       Date:  2015-12-10       Impact factor: 4.379

9.  Changes in Intracellular Na+ following Enhancement of Late Na+ Current in Virtual Human Ventricular Myocytes.

Authors:  Karen Cardona; Beatriz Trenor; Wayne R Giles
Journal:  PLoS One       Date:  2016-11-22       Impact factor: 3.240

10.  Dynamics of sodium current mediated early afterdepolarizations.

Authors:  Daisuke Sato; Colleen E Clancy; Donald M Bers
Journal:  Heliyon       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.